Lessons from the Danish Ban on Feed-Grade Antibiotics by Hayes, Dermot J. & Jensen, Helen H.
Economics Publications Economics
8-2003
Lessons from the Danish Ban on Feed-Grade
Antibiotics
Dermot J. Hayes
Iowa State University, dhayes@iastate.edu
Helen H. Jensen
Iowa State University, hhjensen@iastate.edu
Follow this and additional works at: http://lib.dr.iastate.edu/econ_las_pubs
Part of the Agribusiness Commons, Agricultural and Resource Economics Commons,
Agricultural Economics Commons, and the Economics Commons
The complete bibliographic information for this item can be found at http://lib.dr.iastate.edu/
econ_las_pubs/3. For information on how to cite this item, please visit http://lib.dr.iastate.edu/
howtocite.html.
This Article is brought to you for free and open access by the Economics at Digital Repository @ Iowa State University. It has been accepted for
inclusion in Economics Publications by an authorized administrator of Digital Repository @ Iowa State University. For more information, please
contact digirep@iastate.edu.
CHOICES
The magazine of food, farm and resource issues
Third Quarter 2003 CHOICES 1
A publication of the
American Agricultural
Economics Association
Third Quarter 2003
In June of 2003, McDonald’s Corporation
announced that it would prohibit its direct suppli-
ers from using antibiotics that are important in
human medicine as growth promotants in food
animals after 2004. The company also created a
purchasing preference for companies that work to
minimize antibiotic use. This announcement, cou-
pled with recent Food and Drug Administration
guidance on the same issue, will put pressure on the
US livestock industry to consider alternatives to
feed-grade antibiotics. Denmark recently banned
the use of feed-grade antibiotics in pork production
and has been joined in this action by countries in
the European Union (EU). The ban was imple-
mented first at the finishing stage and then at the
weaning stage. Denmark’s recent experiences with
the withdrawal of antibiotics from feed can help us
to better understand and anticipate the conse-
quences of a similar action in the United States.
Background
Current EU regulations restrict the use of antimi-
crobials—derived from either human or veterinary
therapeutic medicine—as feed-additive growth
promoters in livestock. The European Union cur-
rently restricts the list of approved feed additives to
include only avilamycin, bambermycin, salinomy-
cin, and monensin, and these antibiotic growth
promotants (AGPs) are scheduled to be banned by
2006.
In 1998, the Danish government instituted a
voluntary ban on the use of AGPs in pork produc-
tion at the finishing stage (accompanied by a pen-
alty tax for use). On January 1, 2000, Denmark
banned AGPs at both the weaning and finishing
stages. Denmark provides a suitable market for
evaluating the cost impact of a ban of AGPs: it is an
export-oriented and market-driven production sys-
tem; it maintains excellent records on production
costs and on antibiotic use; and its pork industry is
at least as sophisticated as that of the United States. 
Antibiotic Use
As shown in Figure 1 (based on data from DAN-
MAP 2001; see Danish Veterinary Institute [DVI],
2002), Denmark’s total consumption of antibiotics
in pork production was 154 metric tons (mt) of
active ingredient in 1996, 106 mt of AGPs, and 48
mt of therapeutic use as medication. By 1998,
when antibiotics were banned from use at the fin-
ishing stage, the total use was 106 mt. The use of
AGPs fell by about 50% (from 107 mt to 49 mt),
and therapeutic use remained about constant. By
1999, overall antibiotic use fell to a low of 74 mt.
The effective ban of AGPs at the finishing stage
in 1998 was accomplished through a tax and some
pressure to discontinue the use of subtherapeutic
antibiotics. Danish farm management experts cal-
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Increased problems of disease in postweaning piglets 
The Danish experience suggests that reduced use of antibiotics 
at the weaning stage has had significant animal health effects 
throughout the production system.
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culated the economic value of the subtherapeutic
antibiotics at the finishing stage. Based on their
estimates, farmers were required either to pay a tax
of $2.00 per head on animals for which the prod-
ucts were used or to agree to discontinue use. Poli-
cymakers considered this level of tax “about right.”
Faced with this tax, most producers stopped using
the products at the finishing stage. Farmers
reported very few health problems in their herds—a
result that indicates that most of the benefits of
AGP use at the finishing stage were driven by a
growth-promoting effect plus a small reduction in
mortality. National mortality did increase from 3%
to 3.6% in 1999, but it is not clear that any of this
was due to the ban. The Danes viewed the ban at
the finishing stage as a resounding success. Total
antibiotic use was cut by more than 50%, and few
health problems were encountered.
The ban at the weaning stage in 2000 was
much more difficult for farmers; they reported
some severe health problems, especially in the early
stages of pig production (National Committee for
Pig Production, 2002). Producers responded by
restricting feed for the first two weeks. As piglet
mortality and disease mounted, veterinarians
became more dependent on the use of therapeutic
antibiotics. Although the use of AGPs fell to nearly
zero in 2000, the use of antibiotics as therapeutic
medications increased. Therapeutic medications
were increasingly substituted for the now-banned
AGPs. Thus, the consumption of total antibiotics
increased from 74 mt in 1999 to 81 mt in 2000 and
to 94 mt in 2001. Despite this increase, the overall
level of antibiotic use in 2001 was still limited to
about 60% of the level used in 1996 before the ban
at the finishing stage. On a per-pig basis, the level
in 2001 was estimated to be 3.0 grams per pig,
down from earlier levels (DVI, 2002).
Most of the pig health problems experienced
after the ban were described as problems with post-
weaning diarrhea and also some diarrhea at the fin-
ishing stage. The Danish producers and veterinari-
ans we spoke with reported that the pigs were
weaker and more vulnerable to disease when they
were moved to the finishing barns. The Danish
experience suggests that reduced use of antibiotics
at the weaning stage has had significant animal
health effects throughout the production system.
Future Patterns of Antibiotic Use in Denmark
The Danes have implemented a major effort to
track antibiotic resistance in animal bacterial iso-
lates through DANMAP, the Danish Integrated
Antimicrobial Resistance Monitoring and Research
Programme. Through a parallel program called
VetStat, the Danes are able to monitor the prescrip-
tion of antibiotics by type of antibiotic, by farm,
and by veterinarian because of unique features of
their prescription issuance and reporting system.
According to the veterinarians interviewed, this
reporting system has enabled the use of prescription
information to identify veterinarians and quantify
the use of antibiotics in each swine herd. 
Through the use of this and other controls, the
national authorities believe that they can further
reduce the overall use of antibiotics and that they
have the tools to do so. 
Human Health Impacts and the Law of 
Unintended Consequences
Although human health impacts were not the focus
of our study, the AGP products banned in Den-
mark have less use in human medicine than do the
therapeutic antibiotics that replaced them. Table 1
shows the large increase in the use of human health
Figure 1. Total consumption of antibiotics in Den-
mark. 
Source: DVI, 2001, 2002.
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products such as tetracyclines, penicillins, and mac-
rolides in Danish food animal production. 
We could reasonably conclude that the use of
the human health products in animal production
might be more harmful to human health than the
products they replaced. This logic is supported by
evidence from human health studies in Denmark.
Of particular concern is the increase in antimicro-
bial resistance among Salmonella typhimurium and
Campylobacter jejuni human isolates to tetracycline
and other selected antimicrobials in Denmark in
2001 (Figure 2). This evidence is important,
because the antibiotics that were phased out were
active against gram negative bacteria and could not
have created resistance in gram positive bacteria
such as salmonella or campylobacter. Because of the
health problems, many antimicrobials in use before
the ban were replaced with tetracyclines, which are
active against gram positive bacteria. Tetracycline
use in Denmark went from 12,100 kg in 1998 to
27,900 kg in 2001, and now Denmark has experi-
enced problems with tetracycline resistance in
humans. The link between animal use of antibiotics
and human resistance has not been proven and is
complex, so we cannot conclude that the large
increase in the use of human drugs caused a prob-
lem. However, it is ironic that the policy resulted in
an increase in the use of the products about which
humans are most concerned. This is a classic exam-
ple of how a policy prescription can have conse-
quences that are exactly the opposite of those
intended.
Cost Impacts
Based on what we learned in Denmark and on an
earlier publication that measured the costs associ-
ated with a previous Swedish ban, we calculated the
components of the cost of the ban, as shown in
Table 2. (Details on these cost estimates are avail-
able from the authors.) 
Table 1. Trends in the estimated total usage of antimicrobials for treatment of food animals (kg active 
compound).
Compound 1986 1998 1990 1992 1994 1996 1998 1999 2000 2001a
Tetracyclines 3,800 3,600 9,300 22,000 36,500 12,900 12,100 16,200 24,000 27,900
Penicillins with 
narrow spectrum
3,700 3,800 5,000 6,700 9,400 7,200 14,300 14,700 14,800 17,100
Penicillins with 
extended spectrum
850 1,000 1,200 2,500 4,400 5,800 6,700 6,600 7,600  9,300
Sulfonamides + 
trimethoprim 
2,500 2,200 3,800 7,900 9,500 4,800 7,700 6,800 7,000  7,400
Sulfonamides 22,300 24,200 8,700 5,900 5,600 2,100 1,000 1,000 1,000  800
Macrolides + 
lincosamides 
10,100 9,300 10,900 12,900 11,400 7,600 7,100 8,700 11,100b 14,300
Aminoglycosides 7,800 7,400 7,700 8,500 8,600 7,100 7,800 7,500 10,400 11,900
Others 13,800 6,900 6,700 6,800 4,400 600 650 350 4,500  5,200
Total 64,800 58,400 53,400 73,200 89,900 48,000 57,300 61,900 80,600 94,200
Source: Data for 1986–94 are from the Federation of Danish Pig Producers and Slaughterhouses: Use of Antibiotics in the Pig Production, 
edited by N.E. Rønn. Data for 1996–2000 come from DANMAP 2000 (DVI 2001).
aTaken from DANMAP 2001 (DVI 2002).
bAdjusted from DANMAP 2001 (DVI 2002).
Greater variability in weight at slaughter A ban at the fin-
ishing stage in the United States would create few animal health 
concerns, but it would reduce feed efficiency slightly and 
increase the weight spread of finished animals.
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In addition, we included sort-loss costs of $0.64
per animal. The Swedish and Danish producers did
not have a problem with sort loss, because the pro-
ducers convinced the packers to accept more light-
weight pigs. We included the sort loss in the costs
expected in the United States because of increased
variability of weights expected with the move away
from AGPs and the penalty packers place on the
lighter-weight pigs. We also included capital costs
of $63 million for the additional space needed for
the extra five days post-weaning and $166 million
for the additional sow space. 
Economic Effects
Adding the effects from estimated changes in pro-
ductivity (Table 2) to the sort loss and initial con-
struction costs suggests a first-year impact of $4.50
per head due to the effects of a ban on AGPs. The
$4.50 figure represents a production cost increase
of approximately 4.5%. This cost increases slightly
as more buildings are required in subsequent years
and there are fewer animals but the same fixed
costs. Another comparable estimate for the United
States is a cost of $2.76 per hog (Brorsen et al.,
2002); and, a recent estimate of the cost in Den-
mark of the restricted use is $4 per pig (Jensen,
2003). These estimates suggest the costs are likely
to range from $3 to $4.50 per pig. 
As costs increase, production declines, and
some producers likely would be forced out of busi-
Figure 2. Trends in resistance to selected antimicrobials among isolates from domestically acquired human
cases.
Source: DVI, 2001, 2002.
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Cost Increase Details
The economic impact of a US ban would depend to a large 
extent on the willingness of US veterinarians to increase thera-
peutic use. Our best estimate is that costs would increase by 
approximately $4.50 per animal in the first year. The estimated 
cost increase includes an increase in costs at the finishing stage 
of $1.05 per animal; an increase in costs at the weaning stage of 
$1.25 per animal; an additional veterinary cost of $0.25 per ani-
mal; a vaccine cost of $0.75 per animal; an increase in sort loss of 
$0.65 per animal; and a capital cost of about $0.55 per animal. 
Industry profits would be lower than would otherwise be the 
case as US producers adjust to the ban. The total cost of a ban to 
the US pork industry spread across a ten-year period is esti-
mated to be in excess of $700 million. The expected cost to con-
sumers is an approximate 2% increase in retail prices.
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ness. A lower level of production increases whole-
sale and retail prices, and higher prices help offset
some of the cost increases. The profit impact is
greatest in year one. By year two, the consumer is
paying for most of the cost increase, and the loss in
producer profits would decline. The end result is a
slightly smaller US pork industry, as slightly higher
retail prices would result in lower consumption.
Our estimates show that by adding up the lower
profits per animal for all ten years and summing
across the entire industry, the total cost of a ban
would likely exceed $700 million. The productivity
decline associated with the ban would be recovered
by normal technological advances, but the income
lost to individual producers during the adjustment
phase would be not be recovered.
One important lesson from the Danish experi-
ence is the wide variation in the effects among pro-
ducers. Our results show the economic impacts of a
ban on an “average” or “representative” farm. These
results mask wide differences across farms. With a
ban on AGP use, an all-in, all-out system is neces-
sary in order to reduce the pressure of infectious
diseases. In the United States today, as much as
20% of production still originates on farms that
have not yet adopted all-in, all-out processes. Pro-
ducers who use a mixed or continuous-flow system
might be disinclined to invest in system changes,
and thus they would exit the business. A ban would
likely increase lightweight pigs. The model
accounted for this change as a discount to produc-
ers as they sell on the price grid. By contrast, the
Swedish and Danish industries own their packers
and can better protect the market for smaller ani-
mals.
The Danish experience clearly illustrates the
differences between the effects of a ban at the wean-
ing and finishing stages. The Danes achieved a
large reduction in antibiotic use, and producers
encountered few costs when they banned at the fin-
ishing stage. However, when they imposed a ban at
the weaning stage, they encountered increased post-
weaning health problems leading to increased med-
ication and other costs. In general, the Danes
achieved 80 percent of the benefits for 20 percent
of the costs when they imposed a partial ban, and
they encountered 20 percent of the benefits and 80
percent of the costs when they extended the ban.
Our conclusion is that a ban at the finishing
stage in the United States would create few animal
health concerns, but it would reduce feed efficiency
slightly and increase the weight spread of finished
animals. A ban at the weaning stage would create
serious animal health concerns and a significant
increase in mortality. Faced with these problems,
US veterinarians likely would resort to more pow-
erful therapeutic antibiotics, and the total use of
antibiotics would rise. 
The economic impact of a US ban largely
would depend on the willingness of US veterinari-
ans to increase therapeutic use. Recent experience
in the United Kingdom indicates that the costs and
management required in eliminating use of sub-
therapeutic antibiotics are significant. Under agree-
ments with retailers, UK producers eliminated
AGPs in poultry production in 2000. Now, faced
with significant problems of disease and diarrhea in
their flocks, they are reintroducing antibiotics to
prevent disease. Currently, total antibiotic use has
dropped, but AGP use may increase as one tool in
increased management of animal health. 
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Sweden Denmark
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a These costs totaled $1.25 per animal in Denmark and were not 
broken down into specific productivity impacts.
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